To further evaluate the potential clinical impact of DDAH1 in regulating NPC cell sensitivity to cisplatin‐based chemotherapy and the potential therapeutic benefits of nimotuzumab, we examined the prognostic value of DDAH1 in patients with LANPC receiving cisplatin‐based chemotherapy. The gene discussed is DDAH1; the disease is nasopharyngeal carcinoma.